Compare Novartis AG (NVS) vs Skyworks Solutions Inc (SWKS) Price & Performance

Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.

The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.

Skyworks Solutions (SWKS) trades at $77.17, down 7.5% in the last session, with a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, but revenue and net income have declined year-over-year. The pending merger with Qorvo is a key development, with regulatory clearances obtained, targeting $500 million in synergies. Analyst consensus is a Buy with a $78.80 price target, slightly above the current price.

The outlook is mixed: the Qorvo merger offers growth potential and cost savings, but declining profitability and negative cash flow pose risks. Investor sentiment is cautious due to recent price volatility and earnings pressure. Upside depends on merger execution and market recovery, while downside risks include integration challenges and competitive pressures.